MCI Radiation Oncology Evaluation - March 27, 2026

Please select one: *

I am in active clinical practice

I am retired

I am a student

Other

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Demonstrate the ability to compare how hypofractionation and MR guided radiation therapy compensate for digestive motion in pancreatic cancer, including differences in motion management strategies, margin requirements, and their impact on treatment precision and safety.	Demonstrate the ability to compare how hypofractionation and MR guided radiation therapy compensate for digestive motion in pancreatic cancer, including differences in motion management strategies, margin requirements, and their impact on treatment precision and safety. - 5	Demonstrate the ability to compare how hypofractionation and MR guided radiation therapy compensate for digestive motion in pancreatic cancer, including differences in motion management strategies, margin requirements, and their impact on treatment precision and safety. - 4	Demonstrate the ability to compare how hypofractionation and MR guided radiation therapy compensate for digestive motion in pancreatic cancer, including differences in motion management strategies, margin requirements, and their impact on treatment precision and safety. - 3	Demonstrate the ability to compare how hypofractionation and MR guided radiation therapy compensate for digestive motion in pancreatic cancer, including differences in motion management strategies, margin requirements, and their impact on treatment precision and safety. - 2	Demonstrate the ability to compare how hypofractionation and MR guided radiation therapy compensate for digestive motion in pancreatic cancer, including differences in motion management strategies, margin requirements, and their impact on treatment precision and safety. - 1
Demonstrate the ability to explain how improved local tumor control contributes to a survival benefit in pancreatic cancer, including the ways local progression drives morbidity, limits systemic therapy tolerance, and influences overall treatment outcomes.	Demonstrate the ability to explain how improved local tumor control contributes to a survival benefit in pancreatic cancer, including the ways local progression drives morbidity, limits systemic therapy tolerance, and influences overall treatment outcomes. - 5	Demonstrate the ability to explain how improved local tumor control contributes to a survival benefit in pancreatic cancer, including the ways local progression drives morbidity, limits systemic therapy tolerance, and influences overall treatment outcomes. - 4	Demonstrate the ability to explain how improved local tumor control contributes to a survival benefit in pancreatic cancer, including the ways local progression drives morbidity, limits systemic therapy tolerance, and influences overall treatment outcomes. - 3	Demonstrate the ability to explain how improved local tumor control contributes to a survival benefit in pancreatic cancer, including the ways local progression drives morbidity, limits systemic therapy tolerance, and influences overall treatment outcomes. - 2	Demonstrate the ability to explain how improved local tumor control contributes to a survival benefit in pancreatic cancer, including the ways local progression drives morbidity, limits systemic therapy tolerance, and influences overall treatment outcomes. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice

	5	4	3	2	1
Comparing digestive motion with hypo fraction versus MRgRT.	Comparing digestive motion with hypo fraction versus MRgRT. - 5	Comparing digestive motion with hypo fraction versus MRgRT. - 4	Comparing digestive motion with hypo fraction versus MRgRT. - 3	Comparing digestive motion with hypo fraction versus MRgRT. - 2	Comparing digestive motion with hypo fraction versus MRgRT. - 1
Describing how local controls translate to survival benefit in pancreatic cancer.	Describing how local controls translate to survival benefit in pancreatic cancer. - 5	Describing how local controls translate to survival benefit in pancreatic cancer. - 4	Describing how local controls translate to survival benefit in pancreatic cancer. - 3	Describing how local controls translate to survival benefit in pancreatic cancer. - 2	Describing how local controls translate to survival benefit in pancreatic cancer. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so?

Please provide any additional comments or suggestions.

Name and ABS ID Required to claim MOC

You are here

MCI Radiation Oncology Evaluation - March 27, 2026